Immuno-oncology (IO) takes advantage of the body’s immune system to prevent, control, and eliminate cancer and dates as far back as the 1890s, after a doctor purposely infected a man suffering from an inoperable malignant tumor with bacteria, resulting in his recovery.

Driven in part by the increasing number of biotechs and companies that are conducting IO clinical trials in China and the Asia Pacific—and the higher prevalence of cancers in Asia with high somatic mutations such as melanoma, lung cancer, bladder cancer, stomach and esophageal cancer which are known to be more sensitive to IO therapies—the IO market in the region is expected to increase from roughly US$15 billion in 2019 to an estimated US$28 billion by the end of 2024.

When scouting for oncology innovation globally, we focus on the key strengths of each region. So, how can we complement Asia’s strengths in oncology? Join us in this webinar as we hear from experts from across the Johnson & Johnson Family of Companies on our IO/oncology external innovation strategy and how we work with early-stage companies in a flexible co-collaboration model.

Immediately following the webinar, we’ll be hosting 1:1 partnering meetings with selected companies to discuss their respective oncology solution/technology. Scroll down to apply!